Form 4: Viemed COO Zehnder Reports Equity Transactions

Viemed Healthcare's Chief Operating Officer, William Todd Zehnder, reported routine vesting of restricted stock units and phantom share units, along with new equity grants.

Summary

• William Todd Zehnder, Chief Operating Officer and Director of Viemed Healthcare, Inc., reported several transactions involving common shares, Restricted Stock Units (RSUs), and Phantom Share Units (PSUs).
• On January 17, 2026, Zehnder acquired 26,939 common shares and 6,735 common shares through the vesting and conversion of derivative securities.
• Simultaneously, 8,550 common shares were disposed of to satisfy tax obligations related to RSU vesting, at a per share value of $7.33.
• An additional 6,735 common shares were disposed of for cash settlement of phantom shares, also at $7.33 per share.
• Following these transactions, Zehnder's direct beneficial ownership of common shares was 292,362.
• On January 19, 2026, Zehnder was granted 118,759 new Restricted Stock Units and 29,690 new Phantom Share Units, both vesting in three equal annual installments starting one year from the grant date.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation, including vesting and new grants. These are standard events and do not indicate a significant positive or negative shift in company fundamentals or outlook.

Positives

• The grant of 118,759 new Restricted Stock Units and 29,690 new Phantom Share Units indicates continued long-term incentive alignment between management and shareholders.
• The vesting of previously granted equity awards demonstrates the company's commitment to its compensation structure.

Negatives

• The disposition of 8,550 common shares for tax withholding and 6,735 common shares for cash settlement of phantom shares represents a reduction in direct share ownership, although this is a standard practice for equity compensation.

Future Outlook

The newly granted Restricted Stock Units and Phantom Share Units are scheduled to vest in three equal annual installments beginning on the first anniversary of their January 19, 2026 grant date, indicating a future vesting schedule for these long-term incentives.

Industry Context

This filing reflects standard executive compensation practices within the healthcare industry, where equity awards like RSUs and PSUs are commonly used to align management incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Phantom Share Units (PSUs) as part of executive compensation is a common practice across publicly traded companies, including those in the healthcare sector, aligning executive interests with shareholder returns over multi-year vesting periods.
• The disposition of shares to cover tax obligations upon vesting is a standard and expected event for equity compensation, consistent with practices observed at comparable companies.

Stakeholder Impact

• Shareholders: The transactions represent routine executive compensation activities, which are generally expected and do not directly impact the company's operational performance or financial health. The new grants align management incentives with long-term shareholder value.
• Employees: The equity compensation structure for executives may reflect broader compensation philosophies within the company, potentially influencing employee retention and motivation.

Next Steps

• Future vesting events for the newly granted Restricted Stock Units and Phantom Share Units will occur in three equal annual installments beginning on January 19, 2027.

Key Dates

Keywords

Viemed Healthcare, VMD, Form 4, Insider Trading, Restricted Stock Units, Phantom Share Units, Equity Compensation, Officer Transactions, Director Transactions, Stock Vesting